Romiplostim biosimilar - Intas Pharmaceuticals

Drug Profile

Romiplostim biosimilar - Intas Pharmaceuticals

Latest Information Update: 15 Sep 2016

Price : $50

At a glance

  • Originator Intas Biopharmaceuticals
  • Class Carrier proteins; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Thrombopoietin receptor agonists; Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Idiopathic thrombocytopenic purpura

Most Recent Events

  • 05 Jul 2016 Intas Pharmaceuticals completes a phase III trial in Idiopathic thrombocytopenic purpura in India (SC) (CTRI2015-09-006197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top